Generic Name

Carbamazepine

Brand Names
Carbatrol, Tegretol, Equetro, Epitol, Carbamazepin
FDA approval date: March 11, 1968
Classification: Mood Stabilizer
Form: Tablet, Suspension, Capsule

What is Carbatrol (Carbamazepine)?

Living with epilepsy or chronic nerve pain can deeply affect a person’s sense of safety, focus, and independence. Seizures or sudden episodes of pain can interrupt daily life and make even ordinary tasks unpredictable. Carbatrol (carbamazepine) is a medication that helps bring control and stability back into the lives of people affected by these conditions. 

Carbatrol is an anticonvulsant and mood-stabilizing medication used to treat seizure disorders, certain types of nerve pain, and bipolar disorder. It belongs to a drug class known as dibenzazepine anticonvulsants. Carbatrol is an extended-release formulation of carbamazepine, meaning it delivers medication slowly throughout the day for steady, long-term control of symptoms. It has been a well-established, first-line therapy for decades, trusted for its effectiveness in stabilizing abnormal brain activity and improving quality of life. 

What does Carbatrol do? 

Carbatrol is primarily prescribed to treat epilepsy, a neurological condition characterized by recurrent seizures caused by sudden bursts of electrical activity in the brain. By helping regulate this electrical activity, Carbatrol reduces the frequency and severity of seizures, allowing patients to live with fewer interruptions and greater confidence. 

It’s also used to relieve trigeminal neuralgia, a chronic pain disorder affecting the face. People with this condition experience sudden, intense facial pain triggered by simple actions like chewing or talking. Carbatrol helps by calming the overactive nerves responsible for these painful episodes. 

Additionally, Carbatrol can help stabilize mood swings in bipolar disorder, particularly during manic episodes. It supports emotional balance and helps prevent extreme highs or lows. 

Clinical studies and long-term use have shown that carbamazepine effectively reduces seizure frequency and nerve pain intensity in most patients, making it one of the most widely prescribed and trusted anticonvulsants worldwide (NIH, 2024). 

How does Carbatrol work? 

Carbatrol works by stabilizing the electrical signals in the brain and nerves. In simple terms, it prevents nerve cells from becoming overly excited, a common trigger for seizures and certain types of nerve pain. 

It does this by blocking sodium channels in nerve cells. These channels are responsible for transmitting electrical impulses. When too many impulses fire at once, it can lead to seizures or pain signals. By slowing the flow of sodium into these cells, Carbatrol calms overactive nerves and helps them function more normally. 

This mechanism is also believed to help regulate mood in people with bipolar disorder by balancing neurotransmitter activity in the brain. Clinically, this stabilization of nerve and brain activity reduces the likelihood of seizures, eases nerve pain, and promotes emotional stability helping patients lead safer, more comfortable lives. 

Carbatrol side effects 

Like all prescription medications, Carbatrol can cause side effects. Most are mild and tend to improve as the body adjusts to the medication. However, it’s important to understand both the common and serious reactions. 

Common side effects may include: 

  • Dizziness or drowsiness 
     
  • Nausea or vomiting 
     
  • Unsteadiness or coordination issues 
     
  • Blurred or double vision 
     
  • Mild skin rash 

Serious side effects (rare but important to recognize): 

  • Severe allergic skin reactions (such as Stevens-Johnson syndrome) 
     
  • Unusual bleeding or bruising (possible blood cell changes) 
     
  • Signs of infection (fever, sore throat) 
     
  • Yellowing of the skin or eyes (liver problems) 
     
  • Confusion, slurred speech, or unsteady movements (possible toxicity) 

Because of potential effects on blood cells and liver function, doctors typically perform regular blood tests during treatment to ensure the medication remains safe and effective. 

Who should avoid Carbatrol: 
People with a known allergy to carbamazepine or tricyclic antidepressants, or those with a history of bone marrow suppression, should not take this medication. It should also be used cautiously in patients with liver, kidney, or heart conditions. 

Seek immediate medical attention for signs of allergic reaction, severe rash, or symptoms such as weakness, fever, or dark urine. While these effects are uncommon, prompt attention ensures safe, continued treatment. 

Carbatrol dosage 

Carbatrol is an extended-release capsule taken orally for steady symptom control with fewer daily doses. Swallow capsules whole; do not crush or chew. It can be taken with or without food. Dosage is individualized, starting low and increasing gradually to minimize side effects. 

Due to Carbatrol’s impact on the liver and blood cells, healthcare providers monitor complete blood counts (CBCs), liver function tests (LFTs), and sodium levels to maintain safe and therapeutic ranges.  

Older adults or those with liver or kidney impairment may require lower doses or closer monitoring. Abruptly stopping Carbatrol can cause withdrawal seizures or symptom rebound; therefore, all medication changes must be professionally supervised. 

Does Carbatrol have a generic version? 

Yes. The active ingredient in Carbatrol, carbamazepine, is available as a generic medication approved by the U.S. Food and Drug Administration (FDA). Generic carbamazepine formulations including immediate-release and extended-release form are clinically equivalent to Carbatrol in safety, strength, and effectiveness. 

Carbamazepine, also known as Tegretol or Equetro, may be switched between brand and generic versions under medical supervision for consistent symptom control. 

Conclusion 

Carbatrol (carbamazepine) is a proven and widely used medication that helps control seizures, relieve nerve pain, and stabilize mood. By calming overactive nerve signals in the brain, it allows patients to regain control over their health and daily routines. 

Though requiring careful monitoring and potential side effects, Carbatrol is a highly effective long-term epilepsy treatment. Most patients tolerate it well, achieving significant stability and comfort. Success hinges on consistent use, open communication with your provider, and regular monitoring for safety and effectiveness. With proper care, Carbatrol helps patients live more confident, seizure-free, and pain-controlled lives. 

References 

  1. U.S. Food and Drug Administration (FDA). (2024). Carbamazepine prescribing information. Retrieved from https://www.accessdata.fda.gov 
     
  1. Mayo Clinic. (2024). Carbamazepine (oral route) medication overview. Retrieved from https://www.mayoclinic.org 
     
  1. MedlinePlus. (2024). Carbamazepine: Drug uses, side effects, and precautions. National Library of Medicine. Retrieved from https://medlineplus.gov 
     
  1. National Institutes of Health (NIH). (2024). Anticonvulsant therapies and mechanism of action. Retrieved from https://www.nih.gov 

Approved To Treat

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

There is no latest advances for this treatment

Brand Information

    Carbatrol (carbamazepine)
    WARNING
    SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE
    SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBATROL).
    APLASTIC ANEMIA AND AGRANULOCYTOSIS
    APLASTIC ANEMIA AND AGRANULOCYTOSIS HAVE BEEN REPORTED IN ASSOCIATION WITH THE USE OF CARBAMAZEPINE. DATA FROM A POPULATION-BASED CASE-CONTROL STUDY DEMONSTRATE THAT THE RISK OF DEVELOPING THESE REACTIONS IS 5-8 TIMES GREATER THAN IN THE GENERAL POPULATION. HOWEVER, THE OVERALL RISK OF THESE REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW, APPROXIMATELY SIX PATIENTS PER ONE MILLION POPULATION PER YEAR FOR AGRANULOCYTOSIS AND TWO PATIENTS PER ONE MILLION POPULATION PER YEAR FOR APLASTIC ANEMIA.
    ALTHOUGH REPORTS OF TRANSIENT OR PERSISTENT DECREASED PLATELET OR WHITE BLOOD CELL COUNTS ARE NOT UNCOMMON IN ASSOCIATION WITH THE USE OF CARBAMAZEPINE, DATA ARE NOT AVAILABLE TO ESTIMATE ACCURATELY THEIR INCIDENCE OR OUTCOME. HOWEVER, THE VAST MAJORITY OF THE CASES OF LEUKOPENIA HAVE NOT PROGRESSED TO THE MORE SERIOUS CONDITIONS OF APLASTIC ANEMIA OR AGRANULOCYTOSIS.
    BECAUSE OF THE VERY LOW INCIDENCE OF AGRANULOCYTOSIS AND APLASTIC ANEMIA, THE VAST MAJORITY OF MINOR HEMATOLOGIC CHANGES OBSERVED IN MONITORING OF PATIENTS ON CARBAMAZEPINE ARE UNLIKELY TO SIGNAL THE OCCURRENCE OF EITHER ABNORMALITY. NONETHELESS, COMPLETE PRETREATMENT HEMATOLOGICAL TESTING SHOULD BE OBTAINED AS A BASELINE. IF A PATIENT IN THE COURSE OF TREATMENT EXHIBITS LOW OR DECREASED WHITE BLOOD CELL OR PLATELET COUNTS, THE PATIENT SHOULD BE MONITORED CLOSELY. DISCONTINUATION OF THE DRUG SHOULD BE CONSIDERED IF ANY EVIDENCE OF SIGNIFICANT BONE MARROW DEPRESSION DEVELOPS.
    4ADVERSE REACTIONS
    General: If adverse reactions are of such severity that the drug must be discontinued, the physician must be aware that abrupt discontinuation of any anticonvulsant drug in a responsive patient with epilepsy may lead to seizures or even status epilepticus with its life-threatening hazards.
    The most severe adverse reactions previously observed with carbamazepine were reported in the hemopoietic system and skin (see
    The most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomiting. To minimize the possibility of such reactions, therapy should be initiated at the lowest dosage recommended.
    The following additional adverse reactions were previously reported with carbamazepine:
    Hemopoietic System: Aplastic anemia, agranulocytosis, pancytopenia, bone marrow depression, thrombocytopenia, leukopenia, leukocytosis, eosinophilia, acute intermittent porphyria.
    Skin: Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) (see BOXED WARNING), Acute Generalized Exanthematous Pustulosis (AGEP), pruritic and erythematous rashes, urticaria, photosensitivity reactions, alterations in skin pigmentation, exfoliative dermatitis, erythema multiforme and nodosum, purpura, aggravation of disseminated lupus erythematosus, alopecia, diaphoresis, onychomadesis and hirsutism. In certain cases, discontinuation of therapy may be necessary.
    Cardiovascular System: Congestive heart failure, edema, aggravation of hypertension, hypotension, syncope and collapse, aggravation of coronary artery disease, arrhythmias and AV block, thrombophlebitis, thromboembolism, and adenopathy or lymphadenopathy. Some of these cardiovascular complications have resulted in fatalities. Myocardial infarction has been associated with other tricyclic compounds.
    Immune system disorders: Hypogammaglobulinemia.
    Liver: Abnormalities in liver function tests, cholestatic and hepatocellular jaundice, hepatitis, and hepatic failure.
    Pancreatic: Pancreatitis.
    Respiratory System: Pulmonary hypersensitivity characterized by fever, dyspnea, pneumonitis, or pneumonia.
    Genitourinary System: Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, azotemia, renal failure, and impotence. Albuminuria, glycosuria, elevated BUN, and microscopic deposits in the urine have also been reported. There have been rare reports of impaired male fertility and/or abnormal spermatogenesis.
    Testicular atrophy occurred in rats receiving carbamazepine orally from 4-52 weeks at dosage levels of 50-400 mg/kg/day. Additionally, rats receiving carbamazepine in the diet for 2 years at dosage levels of 25, 75, and 250 mg/kg/day had a dose-related incidence of testicular atrophy and aspermatogenesis. In dogs, it produced a brownish discoloration, presumably a metabolite, in the urinary bladder at dosage levels of 50 mg/kg/day and higher. Relevance of these findings to humans is unknown.
    Nervous System: Dizziness, drowsiness, disturbances of coordination, confusion, headache, fatigue, blurred vision, visual hallucinations, transient diplopia, oculomotor disturbances, nystagmus, speech disturbances, abnormal involuntary movements, peripheral neuritis and paresthesias, depression with agitation, talkativeness, tinnitus, and hyperacusis.
    There have been reports of associated paralysis and other symptoms of cerebral arterial insufficiency, but the exact relationship of these reactions to the drug has not been established.
    Isolated cases of neuroleptic malignant syndrome have been reported with concomitant use of psychotropic drugs.
    Digestive System: Nausea, vomiting, gastric distress and abdominal pain, diarrhea, constipation, anorexia, and dryness of the mouth and pharynx, including glossitis and stomatitis.
    Eyes: Scattered punctate cortical lens opacities, as well as conjunctivitis, have been reported. Although a direct causal relationship has not been established, many phenothiazines and related drugs have been shown to cause eye changes.
    Musculoskeletal System: Bone loss, aching joints and muscles, and leg cramps.
    Metabolism: Fever and chills, decreased levels of plasma calcium leading to osteoporosis, and hyperammonemia have been reported.
    Other: Isolated cases of a lupus erythematosus-like syndrome have been reported. There have been occasional reports of elevated levels of cholesterol, HDL cholesterol, and triglycerides in patients taking anticonvulsants.
    A case of aseptic meningitis, accompanied by myoclonus and peripheral eosinophilia, has been reported in a patient taking carbamazepine in combination with other medications. The patient was successfully dechallenged, and the meningitis reappeared upon rechallenge with carbamazepine.